Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01293058
Other study ID # ASD-1213-16
Secondary ID
Status Completed
Phase Phase 2
First received February 9, 2011
Last updated February 9, 2011
Start date March 2007
Est. completion date June 2007

Study information

Verified date March 2007
Source Isfahan University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority Iran: Ministry of Health
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine which route of administration is better for treatment of opioid overdosed patients


Description:

In intravenous drug abusers (IDUs), as a result of previous intravenous substance abuse, the predictable difficult cannulate exist and cause the delay administration of antidote therapy. Additionally, IDUs are also at increased risk of carrying blood borne infections that could be transmitted to healthcare workers through needle stick injuries. The investigators aimed to compare intranasal administration of naloxone with intravenous route.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date June 2007
Est. primary completion date June 2007
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 15 Years to 50 Years
Eligibility Inclusion Criteria:

- Patients with the range of 15-50 years old

- Who were suspicious to opioid overdoses based on history and having clinical appearance such as miotic pupils with loss of consciousness

- Give response to naloxone with increasing the level of consciousness

Exclusion Criteria:

- Not giving response to naloxone and suspicious to have another reason for loss of consciousness

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Intranasal naloxone
spray naloxone, 0.4 mg/ each 4 minutes till increasing patient level of consciousness
Intravenous
Amp naloxone, 0.4 mg / each 4 minutes till increasing patient level of consciousness

Locations

Country Name City State
Iran, Islamic Republic of Noor university hospital Isfahan

Sponsors (1)

Lead Sponsor Collaborator
Isfahan University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary level of consciousness The investigators evaluated the level of consciousness with Glasgow coma sclae 4 minutes after naloxone administration 4 min after naloxone administration Yes
Secondary blood pressure The investigators evaluated blood pressure 4 minutes after naloxone administration at 4 min after naloxone administration Yes